Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Prasugrel
Drug: Placebo

First Posted Date: 2010-07-21

Last Posted Date: 2012-05-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT01167023

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Folic Acid
Drug: Vitamin B12
Drug: Dexamethasone

First Posted Date: 2010-07-19

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 19

Registration Number: NCT01165021

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sondalo, Italy

A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lispro

First Posted Date: 2010-07-12

Last Posted Date: 2014-04-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01159938

Locations: 🇫🇮
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland

A Study of LY900010 in Erectile Dysfunction

Phase 2

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: LY2452473
Drug: placebo (tadalafil)
Drug: tadalafil
Drug: placebo (LY2452473)

First Posted Date: 2010-07-12

Last Posted Date: 2019-04-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 410

Registration Number: NCT01160289

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: IMC-1121B (ramucirumab)
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Carboplatin (AUC 6)
Drug: Carboplatin (AUC 5)
Drug: Cisplatin

First Posted Date: 2010-07-12

Last Posted Date: 2019-09-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 280

Registration Number: NCT01160744

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, Nottinghamshire, United Kingdom

Notch Inhibitor in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY900009 - Dose Escalation Phase (Part A)
Drug: LY900009 - Dose Confirmation Phase (Part B)

First Posted Date: 2010-07-08

Last Posted Date: 2019-08-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT01158404

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States

A Safety Study in Participants With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: LY2216684 (edivoxetine)
Drug: SSRI

First Posted Date: 2010-07-02

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 608

Registration Number: NCT01155661

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain

A Study in Benign Prostatic Hyperplasia

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil

First Posted Date: 2010-06-29

Last Posted Date: 2013-05-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 97

Registration Number: NCT01152190

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY2189265

First Posted Date: 2010-06-23

Last Posted Date: 2015-02-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 755

Registration Number: NCT01149421

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: solanezumab

First Posted Date: 2010-06-22

Last Posted Date: 2012-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 55

Registration Number: NCT01148498

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy